

# An investigation of the activity of Fulltec Anti-Lice Protector in the treatment of head lice

<b>Submission date</b> 19/04/2011	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 24/05/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 12/02/2021	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Background and study aims:

Head lice are tiny insects that live in hair. They are a common problem, particularly among school-age children. Head lice are spread by direct head to head contact. Although they are harmless, the bites of these lice can cause itching and can be very frustrating for sufferers. Fulltec Anti-Lice Protector is a shampoo based on vegetable oils that is claimed to kill lice by blocking spiracles, usually applied for 15-30 minutes. The aim of this study is to test the effectiveness of Fulltec Anti-Lice Protector in the treatment of head lice using a shortened application time

Who can participate?

People aged 2 years and over who have head lice.

What does the study involve?

Each consenting participant with confirmed louse infestation is treated by applying the Fulltec Anti-Lice Protector to pre-washed and towel dried hair and left for 15 minutes, rinsed and dried to check that this application time is long enough to be effective. This procedure is repeated after 8 days. The presence of headlice are then looked for by combing to look for lice on days 1, 8, and 16 after the initial treatment.

What are the possible benefits and risks?

If the treatment regimen is successful participants benefit from getting rid of their head lice completely. There is a small risk that some participants may experience irritation of the scalp from the shampoo or dryness of the skin afterwards.

Where is the study run from?

Medical Entomology Centre, Cambridge (UK)

When is study starting and how long is it expected to run for?

January 2010 to July 2011

Who is funding the study?

Fulltec AG, Zug, (Switzerland)

Who is the main contact?

Mr Ian F Burgess

ian@insectresearch.com

## Contact information

### Type(s)

Scientific

### Contact name

Mr Ian F Burgess

### ORCID ID

<https://orcid.org/0000-0003-0747-3938>

### Contact details

Medical Entomology Centre

Insect Research & Development Limited

6 Quay Court

Colliers Lane

Stow-cum-Quay

Cambridge

United Kingdom

CB25 9AU

+44 (0)122 381 0070

ian@insectresearch.com

## Additional identifiers

### Protocol serial number

CTFT01

## Study information

### Scientific Title

A single centre, single arm, non randomised study to investigate the activity of Fulltec Anti-Lice Protector in the treatment of head lice

### Study objectives

The aim of this study is to provide evidence of the activity of Fulltec Anti-Lice Protector in the treatment of head louse infection using a shortened application time (15 minutes).

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Cambridgeshire 1 Research Ethics Committee approved on 03/03/2011, ref: 10/H0304/95

### Study design

Single-centre single-arm non-randomised proof of concept study

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Head louse infestation

**Interventions**

Fulltec Anti-Lice Protector shampoo applied to pre-washed and towel dried hair for 15 minutes followed by rinsing, with a repeat treatment 8 days later.

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Fulltec Anti-Lice Protector

**Primary outcome(s)**

Cure of infestation, defined as no evidence of head lice, assessed between completion of the second application of treatment on day 8 and day 16 (the first treatment being applied on day 0).

**Key secondary outcome(s)**

1. Safety of the product monitored by observation for adverse events on days 0, 1, 8, and 16 of the study
2. Acceptability of the product, assessed by a questionnaire at day 1

**Completion date**

09/07/2011

## **Eligibility**

**Key inclusion criteria**

1. Both males and females, aged 2 years and over with no upper age limit
2. People who upon examination, are confirmed to have live head lice
3. People who give written informed consent, or if the participant is under 16 years of age whose parent/guardian gives written informed consent to participate in the study
4. People who will be available for follow-up visits by study team members over the 16 days following first treatment

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Total final enrolment**

31

**Key exclusion criteria**

1. People with a known sensitivity to nuts, coconut, or any of the ingredients in Fulltec Anti-Lice Protector
2. People with a secondary bacterial infection of the scalp (e.g. impetigo) or who have an active long-term scalp condition (e.g. psoriasis of the scalp)
3. People who have been treated with other head lice products within the previous two weeks
4. People who have been treated with the antibiotics co-trimoxazole or trimethoprim within the previous four weeks, or who are currently taking such a course
5. Pregnant or nursing mothers
6. People who have participated in another clinical study within one month before entry to this study
7. People who have already participated in this clinical study

**Date of first enrolment**

01/04/2011

**Date of final enrolment**

01/06/2011

## **Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Medical Entomology Centre**

Cambridge

United Kingdom

CB25 9AU

## **Sponsor information**

## Organisation

Fulltec AG (Switzerland)

## ROR

<https://ror.org/02g1dfh62>

## Funder(s)

### Funder type

Industry

### Funder Name

Fulltec AG (Switzerland)

## Results and Publications

### Individual participant data (IPD) sharing plan

The current data sharing plans for the current study are unknown and will be made available at a later date.

### IPD sharing plan summary

Data sharing statement to be made available at a later date

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	02/12/2020	12/02/2021	Yes	No
<a href="#">Participant information sheet</a>	version V1	13/01/2011	03/02/2017	No	Yes
<a href="#">Participant information sheet</a>	version V1	17/01/2011	03/02/2017	No	Yes
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes